Skip to main content
Top
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

Prognostic factors of carcinoma of the ampulla of Vater after surgery

Authors: Jianguo Zhou, Qian Zhang, Peng Li, Yi Shan, Dongbing Zhao, Jianqiang Cai

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

The purpose of this study was to investigate the prognostic factors of carcinoma of the ampulla of Vater (CAV) after surgery. The clinicopathological factors related to the recurrence and prognosis of 162 CAV patients after surgical resection were retrospectively analyzed using univariate and multivariate methods. The in-hospital mortality rate was 4.32 % and the 5-year disease-free survival and overall survival of the 162 subjects were 55.1 and 51.7 %, respectively. Univariate analysis revealed that an advanced T stage (P = 0.002), lymph nodal metastasis (P = 0.002), poor differentiation (P = 0.006), tumor size (P = 0.033), tumor stage (P = 0.001), carbohydrate antigen (CA) 199 serum levels (P = 0.000), pancreatic invasion (P = 0.001), chemotherapy/radiation therapy (P = 0.006), and jaundice (P = 0.012) were factors that significantly affected the prognosis of CAV. Multivariate analysis showed that the pancreatic invasion (P = 0.009), lymph nodal metastasis (P = 0.009), and increased CA199 serum level (P = 0.001) were independent risk factors of recurrence. The pancreatic invasion, lymph nodal metastasis, and increased CA199 serum level are key prognostic factors of CAV after surgery.
Literature
1.
go back to reference Neugut AI, Jacobson JS, Rella VA. Prevalence and incidence of colorectal adenomas and cancer in asymptomatic persons. Gastrointest Endosc Clin N Am. 1997;7:387–99.PubMed Neugut AI, Jacobson JS, Rella VA. Prevalence and incidence of colorectal adenomas and cancer in asymptomatic persons. Gastrointest Endosc Clin N Am. 1997;7:387–99.PubMed
2.
go back to reference Barauskas G, Gulbinas A, Pranys D, et al. Tumor-related factors and patient’s age influence survival after resection for ampullary adenocarcinoma. J Hepatobiliary Pancreat Surg. 2008;15:423–8.PubMedCrossRef Barauskas G, Gulbinas A, Pranys D, et al. Tumor-related factors and patient’s age influence survival after resection for ampullary adenocarcinoma. J Hepatobiliary Pancreat Surg. 2008;15:423–8.PubMedCrossRef
3.
go back to reference Al Ustwani O, Iancu D, Yacoub R, Iyer R. Detection of circulating tumor cells in cancers of biliary origin. J Gastrointest Oncol. 2012;3:97–104.PubMedCentralPubMed Al Ustwani O, Iancu D, Yacoub R, Iyer R. Detection of circulating tumor cells in cancers of biliary origin. J Gastrointest Oncol. 2012;3:97–104.PubMedCentralPubMed
5.
go back to reference O’Connell JB, Maggard MA, Manunga Jr J, et al. Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol. 2008;15:1820–7.PubMedCrossRef O’Connell JB, Maggard MA, Manunga Jr J, et al. Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol. 2008;15:1820–7.PubMedCrossRef
6.
go back to reference Yoon YS, Kim SW, Park SJ, et al. Clinicopathologic analysis of early ampullary cancers with a focus on the feasibility of ampullectomy. Ann Surg. 2005;242:92–100.PubMedCrossRef Yoon YS, Kim SW, Park SJ, et al. Clinicopathologic analysis of early ampullary cancers with a focus on the feasibility of ampullectomy. Ann Surg. 2005;242:92–100.PubMedCrossRef
7.
go back to reference Shiba H, Misawa T, Fujiwara Y, et al. Glasgow prognostic score predicts therapeutic outcome after pancreaticoduodenectomy for carcinoma of the ampulla of vater. Anticancer Res. 2013;33:2715–21.PubMed Shiba H, Misawa T, Fujiwara Y, et al. Glasgow prognostic score predicts therapeutic outcome after pancreaticoduodenectomy for carcinoma of the ampulla of vater. Anticancer Res. 2013;33:2715–21.PubMed
10.
go back to reference Clary BM, Tyler DS, Dematos P, et al. Local ampullary resection with careful intraoperative frozen section evaluation for presumed benign ampullary neoplasms. Surgery. 2000;127:628–33.PubMedCrossRef Clary BM, Tyler DS, Dematos P, et al. Local ampullary resection with careful intraoperative frozen section evaluation for presumed benign ampullary neoplasms. Surgery. 2000;127:628–33.PubMedCrossRef
13.
go back to reference Lee SY, Jang KT, Lee KT, et al. Can endoscopic resection be applied for early stage ampulla of Vater cancer? Gastrointest Endosc. 2006;63:783–8.PubMedCrossRef Lee SY, Jang KT, Lee KT, et al. Can endoscopic resection be applied for early stage ampulla of Vater cancer? Gastrointest Endosc. 2006;63:783–8.PubMedCrossRef
14.
go back to reference Yoon SM, Kim MH, Kim MJ, et al. Focal early stage cancer in ampullary adenoma: surgery or endoscopic papillectomy? Gastrointest Endosc. 2007;66:701–7.PubMedCrossRef Yoon SM, Kim MH, Kim MJ, et al. Focal early stage cancer in ampullary adenoma: surgery or endoscopic papillectomy? Gastrointest Endosc. 2007;66:701–7.PubMedCrossRef
15.
go back to reference Dixon E, Vollmer Jr CM, Sahajpal A, et al. Transduodenal resection of peri-ampullary lesions. World J Surg. 2005;29:649–52.PubMedCrossRef Dixon E, Vollmer Jr CM, Sahajpal A, et al. Transduodenal resection of peri-ampullary lesions. World J Surg. 2005;29:649–52.PubMedCrossRef
16.
go back to reference Hatzaras I, George N, Muscarella P, et al. Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol. 2010;17:991–7.PubMedCentralPubMedCrossRef Hatzaras I, George N, Muscarella P, et al. Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol. 2010;17:991–7.PubMedCentralPubMedCrossRef
17.
go back to reference Duffy JP, Hines OJ, Liu JH, et al. Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg. 2003;138:941–8.PubMedCrossRef Duffy JP, Hines OJ, Liu JH, et al. Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg. 2003;138:941–8.PubMedCrossRef
18.
go back to reference de Paiva Haddad LB, Patzina RA, et al. Lymph node involvement and not the histopathologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater. J Gastrointest Surg. 2010;14:719–28.PubMedCrossRef de Paiva Haddad LB, Patzina RA, et al. Lymph node involvement and not the histopathologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater. J Gastrointest Surg. 2010;14:719–28.PubMedCrossRef
19.
go back to reference Qiao QL, Zhao YG, Ye ML, et al. Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J Surg. 2007;31:137–43.PubMedCrossRef Qiao QL, Zhao YG, Ye ML, et al. Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J Surg. 2007;31:137–43.PubMedCrossRef
20.
go back to reference Winter JM, Cameron JL, Olino K, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg. 2010;14:379–87.PubMedCrossRef Winter JM, Cameron JL, Olino K, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg. 2010;14:379–87.PubMedCrossRef
21.
go back to reference Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006;140:764–72.PubMedCrossRef Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006;140:764–72.PubMedCrossRef
22.
go back to reference Roland CL, Katz MH, Gonzalez GM, et al. A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma. J Gastrointest Surg. 2012;16:2056–63.PubMedCrossRef Roland CL, Katz MH, Gonzalez GM, et al. A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma. J Gastrointest Surg. 2012;16:2056–63.PubMedCrossRef
23.
go back to reference Sierzega M, Nowak K, Kulig J, et al. Lymph node involvement in ampullary cancer: the importance of the number, ratio, and location of metastatic nodes. J Surg Oncol. 2009;100(1):19–24.PubMedCrossRef Sierzega M, Nowak K, Kulig J, et al. Lymph node involvement in ampullary cancer: the importance of the number, ratio, and location of metastatic nodes. J Surg Oncol. 2009;100(1):19–24.PubMedCrossRef
24.
25.
go back to reference Lee JH, Whittington R, Williams NN, et al. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys. 2000;47:945–53.PubMedCrossRef Lee JH, Whittington R, Williams NN, et al. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys. 2000;47:945–53.PubMedCrossRef
26.
go back to reference Beger HG, Treitschke F, Gansauge F, et al. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg. 1999;134:526–32.PubMedCrossRef Beger HG, Treitschke F, Gansauge F, et al. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg. 1999;134:526–32.PubMedCrossRef
27.
go back to reference Hsu HP, Yang TM, Hsieh YH, et al. Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol. 2007;14:50–60.PubMedCrossRef Hsu HP, Yang TM, Hsieh YH, et al. Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol. 2007;14:50–60.PubMedCrossRef
28.
go back to reference Zhou G, Chiu D, Qin D, et al. The efficacy evaluation of cryosurgery in pancreatic cancer patients with the expression of CD44v6, integrin-β1, CA199, and CEA. Mol Biotechnol. 2012;52:59–67.PubMedCrossRef Zhou G, Chiu D, Qin D, et al. The efficacy evaluation of cryosurgery in pancreatic cancer patients with the expression of CD44v6, integrin-β1, CA199, and CEA. Mol Biotechnol. 2012;52:59–67.PubMedCrossRef
29.
go back to reference Zhou G, Niu L, Chiu D, et al. Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF-α and TSGF after cryosurgery in pancreatic cancer patients. Biotechnol Lett. 2012;34:1235–41.PubMedCrossRef Zhou G, Niu L, Chiu D, et al. Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF-α and TSGF after cryosurgery in pancreatic cancer patients. Biotechnol Lett. 2012;34:1235–41.PubMedCrossRef
30.
go back to reference Zhou J, Hsu CC, Winter JM, et al. Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiother Oncol. 2009;92:244–8.PubMedCentralPubMedCrossRef Zhou J, Hsu CC, Winter JM, et al. Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiother Oncol. 2009;92:244–8.PubMedCentralPubMedCrossRef
31.
go back to reference Narang AK, Miller RC, Hsu CC, et al. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital–Mayo Clinic collaborative study. Radiat Oncol. 2011;6:126.PubMedCentralPubMedCrossRef Narang AK, Miller RC, Hsu CC, et al. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital–Mayo Clinic collaborative study. Radiat Oncol. 2011;6:126.PubMedCentralPubMedCrossRef
Metadata
Title
Prognostic factors of carcinoma of the ampulla of Vater after surgery
Authors
Jianguo Zhou
Qian Zhang
Peng Li
Yi Shan
Dongbing Zhao
Jianqiang Cai
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1153-9

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine